This product is for research use only, not for human use. We do not sell to patients.
Size | Price | Stock |
---|---|---|
100mg | $5000 | Check With Us |
200mg | $7500 | Check With Us |
500mg | $12650 | Check With Us |
Cat #: V4378 CAS #: 380610-27-5 Purity ≥ 99%
Description: Pertuzumab (also known as 2C4; trade name Perjeta) is a humanized monoclonal antibody that acts as a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer. Pertuzumab is used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
Molecular Weight (MW) | 145175.18 |
---|---|
CAS No. | 380610-27-5 |
Synonyms | Pertuzumab |
Protocol | In Vitro | Trastuzumab and Pertuzumab are highly synergistic inhibitors of BT474 breast cancer cell survival. The combination of trastuzumab and Pertuzumab mediates a loss of up to 60% of cells at doses in which individual drugs do not alter cell survival. The combination of trastuzumab and Pertuzumab reduces the percentage of proliferating (S-phase) cells by more than 2-fold. A combination of trastuzumab and Pertuzumab inhibits cell proliferation and survival to a greater degree than does either agent alone. |
---|---|---|
In Vivo | In Calu-3 NSCLC xenografts, monotherapy with pertuzumab or trastuzumab is able to significantly inhibit tumor growth, with treatment-to-control ratios (TCR) of 0.23 and 0.27, respectively. The combination of trastuzumab and pertuzumab produces a dramatically enhanced antitumor activity compared with single-agent treatments (TCR 0.05, resulting in tumor regression and, in 3 of 10 animals, complete tumor remission). Treatment of KPL-4 breast cancer xenografts with either trastuzumab or pertuzumab inhibits tumor growth with TCRs of 0.67 and 0.65, respectively. Pertuzumab maintains antitumor activity after progression on trastuzumab. |
Solvent volume to be added | Mass (the weight of a compound) | |||
---|---|---|---|---|
Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
1mM | 0.0069 mL | 0.0344 mL | 0.0689 mL | 0.1378 mL |
5mM | 0.0014 mL | 0.0069 mL | 0.0138 mL | 0.0276 mL |
10mM | 0.0007 mL | 0.0034 mL | 0.0069 mL | 0.0138 mL |
20mM | 0.0003 mL | 0.0017 mL | 0.0034 mL | 0.0069 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.